Virus Particles and Virus-like Particles-based Vaccines for Cancer Treatment

Zijie Li

doi:10.62051/mczfbm70

Authors

Zijie Li

DOI:

https://doi.org/10.62051/mczfbm70

Keywords:

Virus vaccines; cancer; oncolytic virus; virus-like particles.

Abstract

Virus vaccines in cancer immunotherapy are a promising area in cancer treatments, utilizing viruses to augment the immune response against cancer cells and induce tumor cell death. Oncolytic virotherapy known as virus-based vaccine is an innovative cancer treatment leading by oncolytic virus (OVs) which has shown encouraging outcomes over the last twenty years. This therapy is able to effectively combine with other therapy, for instance radiotherapy and car-t cell therapy. Virus-like particles (VLPs) serve as an antigen presentation platform in cancer therapeutic and preventive applications. Compared with oncolytic virus vaccines, VPLs-based vaccines can directly uptake by immune cells without any infection. Initial virus-based and virus-like particle-based cancer treatments have shown little effectiveness, but progress in molecular engineering, genomics, and molecular analysis offer hope for improving and rejuvenating virus-vaccines in medical settings. However, there are still obstacles like OVs delivery and VLPs modifications in preclinical or clinical trials. It is crucial to figure out the research status and the difference of OVs-based and VLPs-based vaccines.

Downloads

Download data is not yet available.

References

[1] Brown JS, Amend SR, Austin RH, Gatenby RA, Hammarlund EU, Pienta KJ. Updating the definition of cancer. Mol Cancer Res. 2023 Nov 1; 21 (11): 1142 – 7.

[2] Li L, Liu S, Han D, Tang B, Ma J. Delivery and biosafety of oncolytic virotherapy. Front Oncol. 2020 Apr 16; 10: 475.

[3] Mondal M, Guo J, He P, Zhou D. Recent advances of oncolytic virus in cancer therapy. Hum Vaccines Immunother. 2020 Oct 2; 16 (10): 2389 – 402.

[4] Tornesello AL, Tagliamonte M, Buonaguro FM, Tornesello ML, Buonaguro L. Virus-like Particles as Preventive and Therapeutic Cancer Vaccines. Vaccines. 2022 Feb 2; 10 (2): 227.

[5] Abd-Aziz N, Poh CL. Development of oncolytic viruses for cancer therapy. Transl Res. 2021 Nov; 237: 98 – 123.

[6] Truong CS, Yoo SY. Oncolytic Vaccinia Virus in Lung Cancer Vaccines. Vaccines. 2022 Feb 4; 10 (2): 240.

[7] Ylösmäki E, Cerullo V. Design and application of oncolytic viruses for cancer immunotherapy. Curr Opin Biotechnol. 2020 Oct; 65: 25 – 36.

[8] Pandolfi F, Altamura S, Frosali S, Conti P. Key role of DAMP in inflammation, cancer, and tissue repair. Clin Ther. 2016 May; 38 (5): 1017 – 28.

[9] Chen T, Ding X, Liao Q, Gao N, Chen Y, Zhao C, et al. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy. J Immunother Cancer. 2021 Jan; 9 (1): e001647.

[10] Ferrucci PF, Pala L, Conforti F, Cocorocchio E. Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma. Cancers. 2021 Mar 18; 13 (6): 1383.

[11] Kleemann J, Jäger M, Valesky E, Kippenberger S, Kaufmann R, Meissner M. Real-world experience of talimogene laherparepvec (T-VEC) in old and oldest-old patients with melanoma: a retrospective single center study. Cancer Manag Res. 2021 Jul; Volume 13:5699 – 709.

[12] Rohaan MW, Stahlie EHA, Franke V, Zijlker LP, Wilgenhof S, Van Der Noort V, et al. Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial. BMC Cancer. 2022 Dec; 22 (1): 851.

[13] Rahman MM, McFadden G. Oncolytic viruses: newest frontier for cancer immunotherapy. Cancers. 2021 Oct 29; 13 (21): 5452.

[14] Deng L, Yang X, Fan J, Ding Y, Peng Y, Xu D, et al. IL-24-armed oncolytic vaccinia virus exerts potent antitumor effects via multiple pathways in colorectal cancer. Oncol Res Featur Preclin Clin Cancer Ther. 2020 Mar 16; 28 (6): 579 – 90.

[15] Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, et al. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. J Immunother Cancer. 2019 Dec; 7 (1): 6.

[16] Mirbahari SN, Da Silva M, Zúñiga AIM, Kooshki Zamani N, St-Laurent G, Totonchi M, et al. Recent progress in combination therapy of oncolytic vaccinia virus. Front Immunol. 2024 Mar 13; 15: 1272351.

[17] Storozynsky QT, Agopsowicz KC, Noyce RS, Bukhari AB, Han X, Snyder N, et al. Radiation combined with oncolytic vaccinia virus provides pronounced antitumor efficacy and induces immune protection in an aggressive glioblastoma model. Cancer Lett. 2023 May; 562: 216169.

[18] Marelli G, Chard Dunmall LS, Yuan M, Di Gioia C, Miao J, Cheng Z, et al. A systemically deliverable vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer. J Immunother Cancer. 2021 Jan; 9 (1): e001624.

[19] Pakola S, Quixabeira DCA, Kudling TV, Clubb JHA, Grönberg-Vähä-Koskela S, Basnet S, et al. An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage. Front Immunol. 2023 Jul 5; 14: 1171083.

[20] Kudling TV, Clubb JHA, Pakola S, Quixabeira DCA, Lähdeniemi IAK, Heiniö C, et al. Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer. OncoImmunology. 2023 Dec 31; 12 (1): 2241710.

[21] Chen L, Zuo M, Zhou Q, Wang Y. Oncolytic virotherapy in cancer treatment: challenges and optimization prospects. Front Immunol. 2023 Dec 15; 14: 1308890.

[22] Li Q, Tan F, Wang Y, Liu X, Kong X, Meng J, et al. The gamble between oncolytic virus therapy and IFN. Front Immunol. 2022 Aug 25; 13: 971674.

[23] Caldeira JC, Perrine M, Pericle F, Cavallo F. Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines. Viruses. 2020 Apr 27; 12 (5): 488.

[24] Ma XY, Hill BD, Hoang T, Wen F. Virus-inspired strategies for cancer therapy. Semin Cancer Biol. 2022 Nov; 86: 1143 – 57.

[25] Mohsen MO, Speiser DE, Knuth A, Bachmann MF. Virus‐like particles for vaccination against cancer. WIREs Nanomedicine Nanobiotechnology. 2020 Jan; 12 (1): e1579.

[26] Rolih V, Caldeira J, Bolli E, Salameh A, Conti L, Barutello G, et al. Development of a VLP-based vaccine displaying an xCT extracellular domain for the treatment of metastatic breast cancer. Cancers. 2020 Jun 8; 12 (6): 1492.

[27] Mohsen MO, Heath M, Kramer MF, Velazquez TC, Bullimore A, Skinner MA, et al. In situ delivery of nanoparticles formulated with micron-sized crystals protects from murine melanoma. J Immunother Cancer. 2022 Sep; 10 (9): e004643.

[28] Jia LJ, Dong SQ, Yao Y, Ping SL, Li BS. Anti-OX40 antibody combined with HBc VLPs delays tumor growth in a mouse colon cancer model. Biomed Env Sci.